Raye Z Litten

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Medications development to treat alcohol dependence: a vision for the next decade
    Raye Z Litten
    National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA
    Addict Biol 17:513-27. 2012
  2. doi request reprint Alcohol biomarkers in applied settings: recent advances and future research opportunities
    Raye Z Litten
    Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland 20892 9304, USA
    Alcohol Clin Exp Res 34:955-67. 2010
  3. ncbi request reprint Development of medications for alcohol use disorders: recent advances and ongoing challenges
    Raye Z Litten
    Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, 5635 Fishers Lane, Room 2041, Bethesda, MD 20852 1705, USA
    Expert Opin Emerg Drugs 10:323-43. 2005
  4. pmc A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients
    Joanne B Fertig
    Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland, USA
    Alcohol Clin Exp Res 36:1421-30. 2012
  5. pmc The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies
    Raye Z Litten
    Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland
    Alcohol Clin Exp Res 37:2128-37. 2013
  6. pmc A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients
    Raye Z Litten
    Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland 20892, USA
    Alcohol Clin Exp Res 36:406-16. 2012
  7. pmc A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence
    Raye Z Litten
    From the Division of Treatment and Recovery Research RZL, MLR, JBF DEF, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD Department of Psychiatric Medicine BJ, Nat, University of Virginia, Charlottesville, VA Johns Hopkins University School of Medicine KED, ECS, Baltimore, MD Geisel School of Medicine at Dartmouth AIG, MFB, Lebanon, NH University of Pennsylvania Treatment Research Center HMP, KK, Philadelphia, PA Boston University School of Medicine DAC, OS S, Boston, MA Fast Track Drugs and Biologics JR, CS, North Potomac, MD and Decision Sciences Institute Pacific Institute for Research and Evaluation RS, Pawtucket, RI NCIG Study Group members are as follows Boston Medical Center, Boston, MA and Quincy, MA Joanna Piechniczek Buczek, MD, Chris Streeter, MD, Eric Devine, PhD, Courtney Richambault, Laurie Sickles Colaneri, RN University of Virginia, Charlottesville
    J Addict Med 7:277-86. 2013
  8. pmc Moderators of Varenicline Treatment Effects in a Double-Blind, Placebo-Controlled Trial for Alcohol Dependence: An Exploratory Analysis
    Daniel E Falk
    From the Division of Treatment and Recovery Research DF, IC, MR, JF, RL, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD and CSR Incorporated IC, Arlington, VA
    J Addict Med 9:296-303. 2015
  9. ncbi request reprint Self-report and biochemical measures of alcohol consumption
    Raye Z Litten
    Division of Treatment and Recovery Research, National Institute of Alcohol Abuse and Alcoholism, Bethedsa, MD, USA
    Addiction 98:iii-iv. 2003
  10. doi request reprint Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials
    Daniel Falk
    Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland 20892 9304, USA
    Alcohol Clin Exp Res 34:2022-34. 2010

Collaborators

Detail Information

Publications22

  1. pmc Medications development to treat alcohol dependence: a vision for the next decade
    Raye Z Litten
    National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA
    Addict Biol 17:513-27. 2012
    ..Successful implementation of these objectives will result in the development of more efficacious and safe medications, provide a greater selection of therapy options and ultimately lessen the impact of this devastating disorder...
  2. doi request reprint Alcohol biomarkers in applied settings: recent advances and future research opportunities
    Raye Z Litten
    Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland 20892 9304, USA
    Alcohol Clin Exp Res 34:955-67. 2010
    ..Development of more accurate biomarkers will help practicing clinicians to more effectively screen and monitor individuals who suffer from alcohol use disorders...
  3. ncbi request reprint Development of medications for alcohol use disorders: recent advances and ongoing challenges
    Raye Z Litten
    Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, 5635 Fishers Lane, Room 2041, Bethesda, MD 20852 1705, USA
    Expert Opin Emerg Drugs 10:323-43. 2005
    ....
  4. pmc A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients
    Joanne B Fertig
    Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland, USA
    Alcohol Clin Exp Res 36:1421-30. 2012
    ..Previous research suggests that the anticonvulsant levetiracetam may be beneficial in an alcohol-dependent population of very heavy drinkers...
  5. pmc The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies
    Raye Z Litten
    Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland
    Alcohol Clin Exp Res 37:2128-37. 2013
    ..A significant placebo response occurs in alcohol trials, but it is not well understood. The purpose of this study was to characterize the placebo response across multiple naltrexone and acamprosate studies...
  6. pmc A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients
    Raye Z Litten
    Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland 20892, USA
    Alcohol Clin Exp Res 36:406-16. 2012
    ..Atypical antipsychotic medications have been explored with varying results. Prior research suggests that the antipsychotic quetiapine may be beneficial in an alcohol-dependent population of very heavy drinkers...
  7. pmc A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence
    Raye Z Litten
    From the Division of Treatment and Recovery Research RZL, MLR, JBF DEF, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD Department of Psychiatric Medicine BJ, Nat, University of Virginia, Charlottesville, VA Johns Hopkins University School of Medicine KED, ECS, Baltimore, MD Geisel School of Medicine at Dartmouth AIG, MFB, Lebanon, NH University of Pennsylvania Treatment Research Center HMP, KK, Philadelphia, PA Boston University School of Medicine DAC, OS S, Boston, MA Fast Track Drugs and Biologics JR, CS, North Potomac, MD and Decision Sciences Institute Pacific Institute for Research and Evaluation RS, Pawtucket, RI NCIG Study Group members are as follows Boston Medical Center, Boston, MA and Quincy, MA Joanna Piechniczek Buczek, MD, Chris Streeter, MD, Eric Devine, PhD, Courtney Richambault, Laurie Sickles Colaneri, RN University of Virginia, Charlottesville
    J Addict Med 7:277-86. 2013
    ..This is the first multisite clinical trial of varenicline in a population of smokers and nonsmokers with alcohol dependence...
  8. pmc Moderators of Varenicline Treatment Effects in a Double-Blind, Placebo-Controlled Trial for Alcohol Dependence: An Exploratory Analysis
    Daniel E Falk
    From the Division of Treatment and Recovery Research DF, IC, MR, JF, RL, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD and CSR Incorporated IC, Arlington, VA
    J Addict Med 9:296-303. 2015
    ..Given the heterogeneity among alcohol-dependent patients, secondary analyses were conducted to determine whether certain subgroups responded more favorably than others to treatment with varenicline...
  9. ncbi request reprint Self-report and biochemical measures of alcohol consumption
    Raye Z Litten
    Division of Treatment and Recovery Research, National Institute of Alcohol Abuse and Alcoholism, Bethedsa, MD, USA
    Addiction 98:iii-iv. 2003
  10. doi request reprint Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials
    Daniel Falk
    Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland 20892 9304, USA
    Alcohol Clin Exp Res 34:2022-34. 2010
    ..As PSNHDD has been used infrequently in previous alcohol clinical trials, we evaluated the utility and validity of the PSNHDD outcome measure in 2 large alcohol clinical trials...
  11. ncbi request reprint Introduction: National Institute on Alcohol Abuse and Alcoholism workshop on treatment research priorities and health disparities
    Charlene E Le Fauve
    National Institute on Alcohol Abuse and Alcoholism, National Institute of Health, Department of Health and Human Service, Bethesda, Maryland 20892 7003, USA
    Alcohol Clin Exp Res 27:1318-20. 2003
  12. doi request reprint Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety
    Raye Z Litten
    a NIAAA s Clinical Investigations Group NCIG, Division of Medications Development, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland, USA
    Subst Abus 37:286-98. 2016
    ....
  13. pmc Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development
    Raye Z Litten
    NIAAA s Clinical Investigations Group NCIG, Division of Medications Development, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland
    Alcohol Clin Exp Res 40:1368-79. 2016
    ..Our goal in writing this article is to provide a guide on medications development that will aid the alcohol research community in planning, testing, and developing medications for AUD. ..
  14. doi request reprint A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence
    Megan L Ryan
    Division of Medications Development, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA
    Neuropsychopharmacology . 2016
    ..Neuropsychopharmacology advance online publication, 19 October 2016; doi:10.1038/npp.2016.214...
  15. doi request reprint Alcohol medications development: advantages and caveats of government/academia collaborating with the pharmaceutical industry
    Raye Z Litten
    National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group NCIG RZL, MR, DF, JF, Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland
    Alcohol Clin Exp Res 38:1196-9. 2014
    ..This commentary examines the advantages and caveats of government and academia collaborations with pharmaceutical companies. ..
  16. doi request reprint Research opportunities for medications to treat alcohol dependence: addressing stakeholders' needs
    Raye Z Litten
    NIAAA s Collaborative Investigator Group NCIG, Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland
    Alcohol Clin Exp Res 38:27-32. 2014
    ..Addressing these issues will not only help to improve treatment but, as further described, will also open up many new research opportunities for alcohol investigators in the coming decade. ..
  17. ncbi request reprint Recommendations on use of biomarkers in alcoholism treatment trials
    John P Allen
    National Institute on Alcohol Abuse and Alcoholism, Vienna, Virginia, USA
    Alcohol Clin Exp Res 27:1667-70. 2003
    ..Among these roles are serving as inclusion or exclusion criteria for research participants, corroboration of self-report of drinking status, assessment of the safety of the agent being evaluated, and determination of treatment outcome...
  18. ncbi request reprint Combining treatments for alcoholism: why and how?
    Margaret E Mattson
    Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, 5635 Fishers Lane NIH Mail Stop 9304, Bethesda, Maryland 20892 9304, USA
    J Stud Alcohol Suppl . 2005
    ....
  19. pmc Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials
    Daniel E Falk
    Division of Treatment and Recovery Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland
    J Stud Alcohol Drugs 75:335-46. 2014
    ..CPRA was used to demonstrate the efficacy of naltrexone and topiramate on continuous measures of in-treatment drinking-heavy drinking days and drinks per day-and their reductions from pretreatment...
  20. ncbi request reprint Pharmacological treatment of alcohol abuse/dependence with psychiatric comorbidity
    Charlene E Le Fauve
    Division of Clinical and Prevention Research, Treatment Research Branch, NIAAA, Bethesda, Maryland, USA
    Alcohol Clin Exp Res 28:302-12. 2004
    ..The panel focused on social anxiety disorder, depression, bipolar disorder, and schizophrenia...
  21. ncbi request reprint Challenges and opportunities for medications development in alcoholism: an international perspective on collaborations between academia and industry
    Bankole A Johnson
    Department of Psychiatric Medicine, University of Virginia, Charlottesville 22908 0623, USA
    Alcohol Clin Exp Res 29:1528-40. 2005
    ..Swift, MD, PhD; (4) A European Perspective on Medications Development, by Otto M. Lesch, MD, PhD, and (5) A Scandinavian Perspective on Evidence-Based Addiction Treatment, by Mats Berglund, MD...
  22. ncbi request reprint Using acquired knowledge and new technologies in alcoholism treatment trials
    Barbara A Flannery
    Center for Interdisciplinary Substance Abuse Research, RTI International, PO Box 12194, 3040 Cornwallis Road, Research Triangle Park, NC 27709 2194, USA
    Alcohol Clin Exp Res 26:423-9. 2002
    ..Flannery; (4) What should be the primary outcome measures in a clinical trial, by Damaris J. Rohsenow; (5) Innovative strategies for assessing functional outcomes in alcoholism treatment clinical trials, by Ron A. Cisler...